NKMAX to Present 'NK Cell Therapy Clinical and Commercialization Challenges' at International Conference Next Month

[Asia Economy Reporter Hyunseok Yoo] NKMAX announced on the 10th that it will participate in the Innate Killer Summit 2021, an international conference held online from the 23rd to the 25th of next month.

The Innate Killer Summit will bring together experts from major companies and university research institutes studying NK cells and NKT innate immunity to discuss the "potential of cell therapies that are expandable for solid cancer treatment and cost-effective."

At NKMAX, Steven Chen, Chief Technology Officer (CTO) of NKMAX America, will attend and present on "Overcoming manufacturing challenges for the clinical and commercial use of NK cell therapies." He will also explain topics such as "Autologous and Allogenic cell proliferation and activation" and "Reducing development time through the development of new in-factory systems."

The following day, he will discuss "What are the challenges faced in mass production of NK cell therapies," "What regulatory requirements must be met to start manufacturing for clinical trials," and "What strategies exist to improve the cost of therapies."

Meanwhile, this conference marks its 6th anniversary this year. In 2019, NKMAX America also participated as the only domestic company developing NK cell therapies.

This content was produced with the assistance of AI translation services.